ArticleBMC cancer2025
The role of transcription factor TBX19 in melanoma: a comprehensive bioinformatics analysis and cellular experiments.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundMelanoma is a highly aggressive skin cancer with a high mortality rate. Although targeted therapies and immunotherapies have advanced, the prognosis for advanced melanoma remains poor. The identification of novel molecular biomarkers is thus crucial for early diagnosis and prognosis prediction. The transcription factor TBX19 has been linked to various biological processes, but its role in melanoma pathogenesis is not well defined.
methodsWe analyzed the expression patterns and the diagnostic and prognostic significance of TBX19 in melanoma using data from The Cancer Genome Atlas (TCGA). Differentially expressed genes (DEGs) between TBX19 high- and low-expression groups were identified and subjected to functional enrichment analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA), and protein-protein interaction (PPI) network analysis. The relationship between TBX19 expression and immune cell infiltration was evaluated. Furthermore, we investigated TBX19-associated signaling pathways and drug sensitivity using the Genomics of Drug Sensitivity in Cancer (GDSC) database. The functional role of TBX19 was validated through in vitro and in vivo experiments.
resultsTBX19 expression was significantly downregulated in melanoma tissues, and this downregulation was associated with an unfavorable prognosis. Low TBX19 expression was an independent risk factor for poorer overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). Functional enrichment analysis indicated that TBX19-related DEGs were involved in processes such as keratinization and immune response. TBX19 expression showed a positive correlation with the infiltration of T helper cells and Tcm cells, but a negative correlation with mast cell infiltration among others. Moreover, TBX19 expression was linked to the epithelial-mesenchymal transition (EMT) and the RAS-Mitogen-Activated Protein Kinase (RAS-MAPK) signaling pathway, and it influenced sensitivity to several anticancer drugs. In vitro experiments demonstrated that TBX19 knockdown promoted proliferation, migration, and invasion in A375 cells, upregulated cyclin D1, cyclin E1, N-cadherin, and vimentin, and downregulated E-cadherin. Conversely, TBX19 overexpression yielded opposite effects in SK-MEL-1 cells. An in vivo xenograft model confirmed that TBX19 knockdown accelerated tumor growth.
conclusionsTBX19 functions as a tumor suppressor in melanoma, modulating tumor progression, immune infiltration, and drug responses. Our findings reveal TBX19 as a potential diagnostic biomarker and therapeutic target, offering new insights into the molecular mechanisms of melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.